ORTEXORTEX News
Tracking FITB? Get live short interest, options flow, and signals on ORTEX.Sign up free →
FI
Trader NoteFITB

Fifth Third Shorts Rebuild While Analysts Lift Targets

By ORTEX News · Edited by , Editor, ORTEX NewsUpdated 3 min readdata as of 31 Oct 2026, 20:11

Produced automatically from ORTEX data and published under the ORTEX News editorial standards set by Peter Hillerberg, Editor, ORTEX News. How we publish

ShareXLinkedInReddit

FITB gained 1.7% over the past week to close at $53.87, outperforming a median peer return of essentially zero, even as short sellers added to positions at the fastest pace in months and JP Morgan raised its target just two days ago.

Short interest climbed nearly 12% over the week to 35 million shares, or 5.3% of free float. That move reverses what had been a gradual unwind through most of October and brings the position back toward levels last seen at the end of September. The rebuild is notable not because the absolute level is extreme, but because of its speed: from roughly 29.8 million shares on October 19 to 35 million by October 26, a jump of more than 17% in five sessions. Despite that, the borrow market tells a calmer story. Availability is exceptionally loose at 1,374%, meaning lenders hold roughly fourteen times as many shares as are currently borrowed. Cost to borrow has actually fallen 13% over the week to 0.43%, among the lowest levels in the trailing 30-day window. Shorts are rebuilding their position without any friction from the lending pool.

Options traders, meanwhile, are leaning the other way. The put/call ratio has dropped to 0.56, sitting about 1.45 standard deviations below its 20-day average of 0.62 and close to its 52-week low of 0.47. That reflects a meaningful shift toward calls relative to recent norms. The PCR has been trending lower all month: it was above 0.68 in late September and has fallen steadily since. Whatever is driving the short rebuild, options flow is not confirming it.

Analyst activity this week reinforces the constructive case. JP Morgan's Vivek Juneja raised his price target to $60 from $58 on October 30, maintaining an Overweight rating, less than a week after Evercore ISI upgraded the stock to Outperform and lifted its target to $60. Citigroup raised its target to $63 earlier in the month. The consensus sits at buy, with a mean target of $61.39, implying about 14% upside to the current price. Not all the moves were positive: Stephens trimmed its target to $59 and RBC pulled back to $60 from $62, both maintaining positive ratings, suggesting the resets reflect valuation discipline rather than a change in view. The bull case centres on the Comerica integration, with systems conversion completed in Q3 and the full $850 million annualised expense synergy run-rate expected in Q4. Adjusted EPS of $1.13 in Q3 was up 22% year on year, and the bank's CET1 ratio of 10.0% is positioned to support buyback restarts. The bear case focuses on rising new nonaccrual loan inflows and noninterest expense up 68% year on year, a cost load the integration timeline must now justify. The forward P/E of 11.3x and price/book of 1.4x are both up meaningfully over the past 30 days, reflecting the stock's re-rating.

Insider activity this week is mechanical rather than directional. CEO Timothy Spence exercised options on October 28, acquiring shares at strike prices of $26.72 and $29.64, then filed tax-withholding and a small open-market sale the following day. The sale of 8,257 shares at $54.50 on October 29 was not made under a 10b5-1 plan, but read alongside the same-day withholding and exercise, it looks like routine settlement rather than a conviction call. CIO Jude Schramm sold roughly 1,600 shares in small tranches on October 26 at prices just above $53. Net insider activity over the trailing 90 days runs to a disposal of about 28,300 shares valued at $1.5 million, a minor negative in the context of the company's $49 billion market cap. No activist filing is on the 13D register; all five-percent-plus holders are passive index and asset managers, with BlackRock at 9.3% and combined Vanguard entities above 12%.

Closer peers had a weaker week. CFG fell 2% over the same period, PNC was up just 1.5%, and MTB and USB both closed lower. FITB's outperformance is modest but real. The next scheduled earnings event is January 19, 2027. With the Comerica synergy run-rate set to be visible in Q4 results, and the short position rebuilding at pace, the level of new nonaccrual loan inflows in the coming quarter is the number that will either validate the integration story or give the short side its clearest argument yet.

Stocks in this article

See the live data behind this article on ORTEX.

Open FITB on ORTEX →

How this article was generated

Generated
31 Oct 2026, 20:12
Data as of
31 Oct 2026, 20:11
Prompt version
v1.0
Data sources
Short interestCost to borrowUtilizationOptions flowEarningsAnalyst consensusInstitutional positioningORTEX Alpha signalsRecent ORTEX notesAlt Data

ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.